rizatriptan (Maxalt)

11/03/2009 - "Rizatriptan is a 5HT (IB/ID) agonist with proven efficacy in the acute treatment of migraine headache. "
07/01/2005 - "Two-thirds of patients described the efficacy of oral rizatriptan as excellent or very good (62%), and 89% preferred it over their usual medications for acute treatment of migraine attacks. "
10/01/2002 - "Rizatriptan 10-mg wafers were equally effective in the treatment of menstrual and nonmenstrual migraine attacks occurring over 6 months, regardless of the precise definition of menstrual association used and even when the outcome criteria were very stringent. "
01/01/2016 - "These findings confirm that the rizatriptan benzoate oral disintegrating strip is potentially a useful tool for an effective treatment of migraine with improved bioavailability, rapid onset of action and with increased patient compliance. "
07/01/2005 - "For this employed population of patients with migraine, treatment with rizatriptan significantly improved parameters measuring direct medical costs, work and productivity, and health-related quality of life. "

07/01/2012 - "Rizatriptan demonstrated a statistically significant improvement over placebo in eliminating pain and was generally well tolerated in migraineurs aged 12-17 and 6-17 years. "
01/01/2012 - "Two-hour pain relief was significantly greater with rizatriptan compared with placebo (55.0% vs 17.4%, P < .001). "
05/01/2011 - "Pain relief at two hours was significantly greater with rizatriptan compared with placebo (51% vs. 20%, p < .001). "
09/01/2008 - "The percentage of patients reporting 2-hour pain relief was significantly greater for rizatriptan than for placebo for both PMM (73% vs 50%, P = .006) and MRM subgroups (71% vs 52%, P < .001). "
02/01/2008 - "The percentage of patients reporting 2-hour pain freedom was significantly greater for rizatriptan than for placebo (63.5% vs 29.0%; odds ratio = 4.5; 95% confidence interval: 1.7, 11.9; P = .002) in those treating a menstrual attack. "

03/01/2013 - "Compared with the rizatriptan trial conducted in 1999, the 2011 rizatriptan trial reduced the placebo response rate by 6% for headache freedom at the 2-hour posttreatment end point owing to study design. "
05/01/2021 - "Successful Treatment of Airplane Headache with Rizatriptan: Case Report."
06/01/2010 - "The headache was treated with success with 10 mg of wafer rizatriptan and 600 mg of ibuprophen. "
10/01/2009 - "In the rizatriptan responsive population, CGRP levels are elevated beginning with the premonitory period and throughout mild and moderate/severe headache. "
10/01/2009 - "(2) To correlate response to rizatriptan administered during moderate headache with levels of CGRP levels measured in saliva. "

01/01/2002 - "Compared with placebo, rizatriptan significantly improved functional disability at 1.5 and 2 hours, and nausea at 1 and 1.5 hours. "
03/01/2008 - "Pooled studies of rizatriptan analyzing elimination of nausea as a secondary endpoint showed that 65% of rizatriptan patients reported elimination of nausea at 2 hours compared with 41% of patients taking placebo. "
03/01/2008 - "Although not statistically significant, a greater percentage of patients had elimination of nausea at 2 hours with rizatriptan compared with placebo (70.3% vs 62.0%, P = .165, odds ratio [95% CI] = 1.45 [0.86, 2.46]). "
03/01/2001 - "Rizatriptan 10 mg was also more effective than rizatriptan 5 mg, with a significant superiority at 2 h on all measures except for elimination of nausea. "
03/01/2008 - "Although the efficacy of rizatriptan 10 mg ODT for the elimination of migraine-associated nausea was comparable to that seen in previous rizatriptan trials, the higher-than-usual placebo response prevented a finding of a statistically significant difference. "

02/01/2011 - "In this double-blind, randomized, placebo-controlled study we measured motion sickness in response to a complex vestibular stimulus following pretreatment with either rizatriptan or a placebo. "
02/01/2011 - "Results indicated that of the 15 subjects who experienced vestibular-induced motion sickness when pretreated with placebo, 13 showed a decrease in motion sickness following pretreatment with rizatriptan as compared to pretreatment with placebo (P < 0.02). "
02/01/2011 - "A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation. "
02/01/2011 - "Rizatriptan reduces vestibular-induced motion sickness in migraineurs."
08/06/2009 - "These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. "